News

Mr Prondzynski brings strong executive management and diverse global experience from leadership positions held at multinational healthcare companies. The addition of Mr Prondzynski expands Hospira’s board to 10

Mr Przybyl is replacing Tom Anderson, Ani’s founding CEO, who is leaving to pursue other opportunities. Mr Anderson will remain on Ani’s board of directors. Most recently, Mr

According to the company, the medical device expands its portfolio, because the DVS-HFT dosimeter is specifically calibrated for use with radiation therapy protocols that give patients higher single

In his new position, Dr Nielsen, a founder of Merrimack who has been with the company since inception, continues to be responsible for the strategic direction of the

A total of $3 million of additional milestone payments from Ovation are pending as a result of the approval of ATryn by the FDA. In addition to the

The abbreviated new drug application approval is the result of an extensive, multi-year development program. Efforts to commercialize the product are now being pursued by Synerx. Ovide lotion

Highlights Pre-tax profits increased 128.3% to GBP6.8m (H1 2008: GBP3 million before potential offer related costs of GBP0.25 million). Product range expanded by 17.3% to 47,870 (31 December

The trial assessed the safety and efficacy of Bio-Seal in patients undergoing lung biopsy procedures and demonstrated a statistically significant clinical benefit in the group receiving BioSeal. The

Teva had indicated it was prepared to launch the generic version prior to the resolution of outstanding patent litigation currently being heard by the US District Court of